Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury - (NOSTRA Phase III Trial): A Confirmatory, Placebo-controlled, Randomised, Double Blind, Multi-centre Study

Trial Profile

Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury - (NOSTRA Phase III Trial): A Confirmatory, Placebo-controlled, Randomised, Double Blind, Multi-centre Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Ronopterin (Primary)
  • Indications Brain injuries
  • Focus Registrational; Therapeutic Use
  • Acronyms NOSTRA-III
  • Sponsors vasopharm BIOTECH
  • Most Recent Events

    • 15 Mar 2018 According to a vasopharm BIOTECH media release, the company has recruited half of the 220 planned patients. Six month extended Glasgow Outcome Scale (eGOS) is allowed for the 110th eligible patient recruited and the company expect feedback from the DMC in Q4 2018.
    • 15 Mar 2018 Planned number of patients changed from 232 to 220, according to a vasopharm BIOTECH media release.
    • 06 Sep 2016 According to a Vasopharm media release, data read-out (final clinical report) of the study is estimated for mid-2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top